Safety and Efficacy of Oral Mifepristone for Cervical Ripening in Single Live Intrauterine Term Unscarred Pregnancies

口服米非司酮促进单胎活胎足月无瘢痕妊娠宫颈成熟的安全性和有效性

阅读:1

Abstract

BACKGROUND: Mifepristone results in cervical ripening in females undergoing pregnancy termination. It causes cervical ripening via blockage of progesterone receptors. AIM: The present study aimed to assess the safety and efficacy of oral Mifepristone for cervical ripening in single-live intrauterine term unscarred pregnancies. METHODS: The present study assessed 200 single live-term intrauterine unscarred pregnancies. All were induced using oral mifepristone in 400 mg dose after assessment of BS. A reassessment of BS was done after 24 hours and if needed (in BS < 6), 0.5 mg instilled dinoprostone was given intracervical in 1-3 doses at 6-hour intervals. In BS > 6, subjects were sent to the labor room for oxytocin infusion and ARM, if needed. BS gains after 24 hours, perinatal outcomes, delivery route, and induction to delivery interval were assessed. RESULTS: The mean birth weight in study subjects was 2862.5 ± 85.2 grams. delivery mode was cesarean, outlet forceps delivery, ventouse delivery, and normal delivery in 8.5% (n = 17), 1.55% (n = 3), 3% (n = 6), and 87% (n = 174) study subjects respectively. Asphyxia or need for admission to NICU was reported in 4% (n = 8) of study subjects. re was 0.5% (n = 1) perinatal death in the study. Mean APGAR scores at the 1(st) and 5(th) minute were 8 and 9 respectively. CONCLUSIONS: Mifepristone is efficacious and safe for inducing labor and cervical ripening in subjects with full-term pregnancy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。